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The aim of this study is to identify the exact mechanism(s) by
which cytoskeletal structures are modulated during bone
resorption. In this study, we have shown the possible role of
different actin-binding and signaling proteins in the regulation
of sealing ring formation. Our analyses have demonstrated a
significant increase in cortactin and a correspondingdecrease in
L-plastin protein levels in osteoclasts subjected to bone resorp-
tion for 18 h in the presence of RANKL,M-CSF, and native bone
particles. Time-dependent changes in the localization of L-plas-
tin (in actin aggregates) and cortactin (in the sealing ring) sug-
gest that these proteinsmay be involved in the initial andmatura-
tion phases of sealing ring formation, respectively. siRNA to
cortactin inhibits thismaturation process but not the formation of
actin aggregates. Osteoclasts treated as above but with TNF-
demonstrated very similar effects as observed with RANKL. Oste-
oclasts treated with a neutralizing antibody to TNF- displayed
podosome-like structures in the entire subsurface and at the
periphery of osteoclast. It is possible that TNF- andRANKL-me-
diated signaling may play a role in the early phase of sealing ring
configuration (i.e. either in the disassembly of podosomes or for-
mation of actin aggregates). Furthermore, osteoclasts treated with
alendronateorv reduced the formationof the sealing ringbutnot
actin aggregates. The present study demonstrates a novel mecha-
nistic link between L-plastin and cortactin in sealing ring forma-
tion. These results suggest that actin aggregates formed by L-plas-
tin independent of integrin signaling function as a core in
assembling signalingmolecules (integrinv3, Src, cortactin, etc.)
involved in thematuration process.
Osteoclasts, themultinucleated and terminally differentiated
giant cells, are involved in bone resorption. The adhesion of
osteoclasts to the bone during bone resorption leads to the for-
mation of the clear zone, an actin-rich ring-like adhesion zone
circumscribing an area of bone resorption. Formation of a clear
zone or sealing zone (also known as the sealing ring) has been
considered to be a marker of osteoclast activation and is funda-
mental to the process of osteoclast bone resorption. Sealing
ring formation is mediated by the dynamics of the actin
cytoskeleton. Distinct pathways and signaling molecules have
been shown to play roles in the organization of the sealing ring
during bone resorption. Our previous observations in gelsolin
null (Gsn/)2 osteoclasts demonstrated that deficiency of this
protein blocks podosome assembly and motility. However, the
cells still exhibit sealing ring and matrix resorption (1). There-
fore, Gsn/ osteoclasts are capable of resorbing bone, but the
resorbed areas are small due to the absence of podosomes and
the resulting hypomotile nature of osteoclasts (1).Observations
in Gsn/ osteoclasts also suggest that the organization of the
sealing ring presumably reflect changes in the role of actin-
binding proteins. Spatial configurations of actin filaments by
actin-binding proteins (ABPs) account for the highly specific
changes in cell shape during migration and bone resorption.
ABPs assist in stabilizing and rearranging the organization of
the actin cytoskeleton in response to external stimuli or during
cell migration and adhesion. A few of the ABPs have been iden-
tified as having a role in osteoclast function (1–6).
Wiskott-Aldrich syndrome protein (WASP) is one of the
ABPs, and it has a role in sealing ring formation and bone
resorption in osteoclasts (7, 8). It is also a binding partner for
c-Src family protein-tyrosine kinases (7, 9). Calle et al. (8) have
demonstrated that osteoclasts from WASP knock-out mice
failed to demonstrate a sealing ring, and these osteoclasts are
less resorptive. Expression ofWASP restores normal cytoarchi-
tecture in these osteoclasts. Most recently, we have demon-
strated that a phosphatase called PTP-PEST is involved in the
dephosphorylation of Src at Tyr527 and phosphorylation of Src
at Tyr418 in the catalytic site (10). This resulted in activation of
Src and interaction of Src, cortactin, and Arp2/3 complex with
WASP.WASP, which is identified in the sealing ring of resorb-
ing osteoclasts, also exhibited interaction with Src, PYK2, cor-
tactin, PTP-PEST, Pro-Ser-Thr phosphatase-interacting pro-
tein (PST-PIP), and Arp2/3 in immunostaining analyses (7).
Furthermore, WASP integrates signals from Rho, Cdc42, and
kinases to bind and stimulate actin polymerization and sealing
ring formation in osteoclasts (5, 7, 10). Experiments with
WASP peptides containing Pro-rich and Tyr(P)294-containing
peptides demonstrated significant effects on osteoclast signal-
ing and sealing ring formation (11). Modulation of the phos-
phorylation state of WASP by kinase(s) assists in integrating
multiple signaling molecules that play a part in the assembly of* This work was supported, in whole or in part, by National Institutes of
Health, NIAMS, Grant AR46292. This work was also supported by bridge
funding provided by the American Society for Bone andMineral Research.
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the sealing ring. Integrin v3 signaling plays a key role in this
process.We suggest this based on observations that osteoclasts
treated with osteopontin, a ligand for v3, increase interac-
tion of signaling proteins with WASP, formation of the sealing
ring, and bone resorption (7).
Mounting evidence has demonstrated the ability of the inte-
grin v3-mediated pathway to induce osteoclast activity and
bone resorption. Formation of signal-generating complex con-
sisting of Src, PYK2, focal adhesion kinase, p130cas, c-Cbl, and
PI3K associated with v3 has been shown to play roles in the
organization of the sealing ring during bone resorption (7,
12–19) (for a review, see Ref. 20). An inhibitor to v, RGD
mimetics, and v3-blocking antibodies inhibit bone resorp-
tion in vitro and in vivo, suggesting that this integrin plays an
important role in osteoclast function (21–23). Integrin v3-
associated proteins integrate multiple signaling pathways and
signaling molecules that partake in the assembly of the sealing
ring during bone resorption and podosome assembly/disas-
sembly during migration in osteoclasts.
The importance of TNF- has been implicated in osteoclas-
togenesis and the bone loss that occurs in inflammatory dis-
eases, such as rheumatoid arthritis and periodontitis (24–29).
Fuller et al. (24) have shown that TNF- potently directly acti-
vates osteoclasts, and actin rings were formed rapidly in
response tominuscule concentrations of TNF-. TNF-was as
potent as receptor activator of NF-B ligand (RANKL) in oste-
oclast activation and even more effective in activation than
osteoclast formation. It seems that TNF- has the potentiality
to act by itself and synergize with RANKL in osteoclast differ-
entiation and bone resorption. Further investigations on the
spatially and temporally regulated functions of actin-binding
proteins and pathways are necessary to identify their role in
actin cytoskeleton dynamics during bone resorption.
Osteoclasts may contain a variety of actin-binding proteins
besides WASP, gelsolin, profilin, and Cap Z. However, it is not
clear how these proteins specifically operate at the level of
assembly of actin-related structures during bone resorption.
The focus of this paper is to address how the sealing ring, a
structure fundamental to the function of the osteoclast, is orga-
nized and regulated. Therefore, to identify the key proteins
involved in sealing ring formation as well as to dissect the
dynamic mechanisms that govern the formation of the sealing
ring, we have used the novel proteomic approach to profile the
key regulatory proteins in osteoclasts subjected to bone resorp-
tion. We have shown here that mouse osteoclasts incubated
with native bone particles demonstrated a significant increase
in cortactin and decrease in L-plastin as compared with oste-
oclasts not exposed to bone particles for 16–18 h in the pres-
ence of RANKL and M-CSF. Therefore, this increase is related
to the bone resorption activity of osteoclasts. We have also
shown here that formation of secondary actin adhesive aggre-
gates represents part of the phenotypic changes observed prior
to sealing ring formation onmineralizedmatrix. L-plastin has a
regulatory role in the formation of this structure by its actin
bundling property. An inhibitor to v blocked sealing ring for-
mation. However, these cells displayed actin aggregates. On the
contrary, osteoclasts treated with a neutralizing antibody to
TNF-, and an inhibitor to Src demonstrated punctate podo-
some-like structures in the entire subsurface and at the periph-
ery of the osteoclasts. Failure of formation of actin aggregates in
these osteoclasts suggests that TNF--mediated signaling may
have a role in the onset of sealing ring formation. Src may have
roles at the early and late stage of sealing ring formation.
EXPERIMENTAL PROCEDURES
Reagents—Antibody to L-plastin (SC-16657), actin (SC-
8432), GAPDH (SC-32233), p130cas (SC-859), PYK2 (SC-1514),
WASP (SC-13139), c-Src (SC-8056), anti-phosphotyrosine
(PY20; SC-508), v (SC-6617), and 3 (SC-6627) as well as
siRNA to cortactin (SC-35093) and control RNAi (SC-44233)
were bought from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). Phosphoserine antibody was purchased from Zymed Lab-
oratories Inc., Inc. (San Francisco, CA). Cortactin (H222, cata-
log no. 3503) antibody was purchased from Cell Signaling
Technology, Inc. (Danvers, MA). Antibodies to GAPDH and
TNF- (anti-mouse; catalog no. 10950) were bought from
Abcam Inc. (Cambridge, MA). Recombinant TNF- and M-
CSF proteins and TNFR1 (TNF- receptor 1) antibody were
purchased from R & D Systems (Minneapolis, MN). Cyclo-
RGD peptide (catalog no. PCI-3661-P1) was purchased from
Peptides International (Louisville, KY). Protein estimation rea-
gent, molecular weight standards for proteins, and PAGE
reagents were bought from Bio-Rad. Cy2- and Cy3-conjugated
secondary antibodieswere purchased from Jackson Immunore-
search (West Grove, PA). HRP-conjugated secondary antibod-
ies for immunoblotting were obtained from GE Healthcare.
pEGFP-actin vector was bought from Clontech. Rhodamine-
phalloidin and other chemicals were purchased from Sigma.
Preparation of Osteoclast Precursors from Mice—C57/BL6
mice were used for osteoclast preparation as described previ-
ously (7). These mice were either purchased from Harlan Lab-
oratory or generated in the animal facility of the University of
Maryland Dental School. Breeding and maintenance were car-
ried out as per the guidelines and approval of the institutional
animal care and use committee. Osteoclasts were generated in
vitro using mouse bone marrow cells as described previously
(7).
Purification of Glutathione S-Transferase (GST)-fused RANKL—
pGEX vector containing RANKL cDNAwas expressed in Esch-
erichia coli as GST fusions as described previously (30). SDS-
PAGE and Coomassie Blue staining tested the purity of the
RANKL. Accurate protein content of the purified RANKL pro-
teinwas determined by densitometric quantification of the pro-
tein bands separated by SDS-PAGE using known concentra-
tions of BSA as a standard.
Preparation of Osteoclast Lysate after Various Treatments—
After flushing the marrow cells for osteoclast differentiation,
mouse long bones (free of cells inside and muscles outside)
werewashed extensively with PBS and kept in ethanol until use.
Long bones were air-dried in hood and homogenized by a
miniblender. Bone particles were sieved, and bone particles
60–80 m in size were used for experiments. The multinucle-
ated osteoclasts were seen from day 4 onward, as shown in Fig.
2. At this stage, osteoclasts were added with sterile native bone
particles. 100g of bone particles were added to a well of 6-well
cell culture plates. Three to four wells were used per condition.
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Osteoclasts were treated with () and without () bone parti-
cles for 16–18 h in the presence of macrophage colony-stimu-
lating factor (10 ng/ml) and RANKL (50–60 ng/ml).
Some cultures were treated with mouse TNF- (20 ng/ml)
and bisphosphonates (alendronate or pamidronate, 50 M) at
37 °C. Bisphosphonate stocks (1mM) weremade in PBS or ster-
ile H2O (31). Cells were treated with bisphosphonates in the
presence of bone particles, M-CSF, and RANKL. Prior to the
addition of TNF-, osteoclasts generated with RANKL and
M-CSF were washed extensively with serum-free alpha-mini-
mum essential medium and incubated with the same for 30
min. Subsequently, adherent cells were detachedwith stripping
solution (catalog no. 25056-CL; Cellgro by Media Tech, Inc.,
Herndon, VA) as described previously (32). Cells were replated
in MEM containing 10% fetal bovine serum (FBS), M-CSF and
TNF-. Cultures treated with TNF- do not contain RANKL.
Based on dose-dependent studies, cells were neutralized with
40–50 ng/ml TNF- antibody (goat polyclonal anti-mouse
TNF-; catalog no. ab10950, Abcam) and 3–5 g/ml anti-
mouse TNFR1 (MAB430) antibody. To enhance the blocking
effect, cells were preincubated with the antibody of interest for
60–90minprior to theadditionofTNF-andM-CSF. Incubation
was continued for 12–14 h for the bone resorption assay and
immunostaining analyses.Normal serumwasused as a control for
the antibody treatment. We have performed a trypan blue dye
(Sigma T8154) exclusion test to determine the viability of oste-
oclasts after various treatments. Cells demonstrated clear cyto-
plasm with no inclusion of blue dye. Osteoclasts were viable after
various treatments, such as bone particles, bisphosphonates, v
inhibitor, Src inhibitor, and anti-TNF-.
Following various treatments, osteoclasts were washed three
times with cold PBS and lysed in a radioimmune precipitation
buffer (10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1% deoxy-
cholate, 1% Triton X-100, 0.1% SDS, 1% aprotinin, 2mM PMSF,
100 M Na3VO4, and 1% aprotinin), as described previously
(33). Cells were rocked on ice for 15 min and scraped off with a
cell scraper. Cell lysates were centrifuged at 15,000 rpm for 5
min at 4 °C, and the supernatant was saved. Protein contents
were measured using Bio-Rad protein assay reagent.
SDS-PAGE andWestern Analysis—About 50–100g of pro-
tein was used for 10% SDS-PAGE. After electrophoresis, the
gels were washed and stained with Coomassie Brilliant Blue for
2–3 h as described previously (34). About 100–150 g of pro-
tein was used for immunoblotting analysis. The proteins were
transferred to a PVDF membrane for Western analysis. Blots
were blocked with 10% milk in PBS containing 0.5% Tween
(PBS-T) for 2–3 h and then incubated with 1:1000 dilutions of
primary antibody of interest for 2–3 h.After threewashes for 10
min each with PBS-T, the blot was incubated with a 1:1000
dilution of peroxidase-conjugated species-specific respective
secondary antibody for 2 h at room temperature. After three
washes for 10 min each with PBS-T, protein bands were visual-
ized by chemiluminescence using the ECL kit (Pierce). Blocking
and immunoblottingwere performedwith 5%BSA inPBS-T for
phosphotyrosine antibody (PY20) (32).
Immunohistochemistry and Actin Staining—Osteoclast pre-
cursors (105 cells/coverslips) were cultured on dentine slices
and incubated for different time periods as indicated in Figs. 1,
5, 6, and 7. Osteoclasts were fixed with 3% paraformaldehyde
for 20min andpermeabilizedwith 0.1%TritonX-100 in PBS for
5min as described previously (5). Background fluorescencewas
blocked by incubating cells with either 5% horse serum or 5%
BSA in PBS for 30–45 min at 4 °C. The cells were washed and
incubated with primary antibodies (cortactin, 3, or L-plastin)
of interest (1:100 dilutions) in the blocking solution for 2 h at
4 °C. The primary antibodies were detected with either Cy2-
or FITC-conjugated secondary antibody (1:100 dilutions). Cells
stained for cortactin,3, or L-plastinwere stained for actinwith
rhodamine-phalloidin, as described previously (35). The cells
were washed and mounted on a slide in a mounting solution
(Vector Laboratories) and sealed with nail polish. Immuno-
stained osteoclasts were photographedwith a Bio-Rad confocal
laser-scanning microscope. Images were stored in TIF image
format and processed by Adobe Photoshop (Adobe Systems
Inc., Mountain View, CA).
Actin Staining with Rhodamine-Phalloidin—Cells were fixed
and permeabilized with 3.7% paraformaldehyde and 0.1% Tri-
ton X-100 for 10 min. Cells were then washed with PBS con-
taining 5 mM EGTA (PBS/EGTA) and stained for actin with
rhodamine-phalloidin (1:1000 dilution; Sigma) as described
previously (2). Actin-stained cells were viewed and photo-
graphed on a Bio-Rad confocal laser-scanning microscope.
Images were stored in TIF image format and processed by
Adobe Photoshop (Adobe Systems Inc.). Sealing (actin) rings
were counted in osteoclasts (300–350), and significance was
calculated as described below.
Bone Resorption Assay in Vitro—Bone resorption assay was
performed as described previously (37). Osteoclasts were cul-
tured on dentine slices and incubated for 16–18 h. Subse-
quently, dentine slices were scanned in confocal microscopy to
determine the resorbed area. Images were stored in TIF format
and processed by Adobe Photoshop (Adobe Systems Inc.).
Statistical Analysis—All values were mean S.E. of three or
more experiments done at different times normalized to
intraexperimental control values. A value of0.05 was consid-
ered significant. For statistical comparisons, analysis of vari-
ance was used with Bonferroni corrections (INSTAT for IBM
version 2.0, GraphPad software).
RESULTS
Analysis of Time-dependent Changes in Cytoskeletal
Organization during Bone Resorption
During the process of bone resorption, osteoclasts un-
dergo reorganization of actin cytoskeleton. Some of the ear-
lier mechanisms required for generation and maturation of
the sealing zone have not been studied. Therefore, we pro-
ceeded to establish the sequential changes in the morphol-
ogy and organization of actin filaments in osteoclasts sub-
jected to bone resorption in vitro. Osteoclasts plated on
dentine slices were fixed at the indicated time and stained
with rhodamine-phalloidin for actin. Fig. 1 illustrates time-de-
pendent changes in the organization of actin cytoskeleton.
Between 1 and 3 h, osteoclasts begin to spread on bone by
adhering to the bone surface through the formation of second-
ary actin aggregates, which function as secondary adhesive
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structures (indicated by the arrows in Fig. 1A). These struc-
tures provide traction for membrane extensions, as shown in
Fig. 1A. Cells are outlined in Fig. 1A. Formation of secondary
actin aggregates and spreading of osteoclasts increase the surface
area of osteoclasts (Fig. 1, A–C). These secondary adhesive struc-
tures are different from typical podosome structures observed in
osteoclasts during adhesion and migration (1, 36). Maturation of
actin aggregates to the sealing ring takes place from 6 h onwards.
Osteoclasts exhibit either single ormultiplemature and functional
sealing rings between 8 and 12 h (Fig. 1, B andC).
Osteoclasts Migrated toward and Adhered to the Native Long
Bone Particles
Osteoclasts subjected to bone resorption undergo consider-
able changes in morphology due to reorganization of actin
cytoskeleton, as shown in Fig. 1. Therefore, we determined the
changes in morphology of osteoclasts incubated with native
bone particles (Fig. 2). Osteoclast precursors were observed on
day 4 or 5 in culture (Fig. 2B). Native long bone particles ofmice
(60–80 m; Fig. 2A) were added to cells at this stage (100
g/well in a 6-well cell culture plate) for 16–18 h in the pres-
ence of RANKL (40–50 ng/ml) and M-CSF (10 ng/ml), as
described under “Experimental Procedures.” Pictures were
taken in an inverted phase-contrast microscope (Fig. 2, A–D).
Migration of osteoclasts toward the particles was observed at
2 h (C), and attachment of osteoclasts to bone was observed at
4 h (D).Osteoclasts attached to bone particleswere indicated by
arrowheads (C andD). Similar observationswere found in short
term live cell analysis of osteoclasts expressing GFP-actin and
incubated with dentine slices (supplemental Fig. S1, A and B).
Analysis of Expression Profile of Proteins in Osteoclasts
Subjected to Bone Resorption
Lysates (50 g) made from osteoclasts incubated with ()
and without () bone particles for 16–18 h in the presence of
RANKL and M-CSF were used for SDS-PAGE and Coomassie
Blue staining (Fig. 3A). A dramatic increase in 80–85-kDa pro-
tein and a decrease in 65-kDa protein were observed (Fig. 3A,
lanes 1 and 2). These proteins were identified as cortactin and
L-plastin by immunoblotting analyses with respective antibod-
ies (Fig. 3A, lanes 3 and 4). Lysates (500 g) made from oste-
oclasts treated with or without bone particles were subjected to
two-dimensional gel electrophoresis (supplemental Figs. S2
and S3). Two-dimensional gel electrophoresis and mass spec-
trometry (MS) analyses corroborate the above findings. The
major spots in two-dimensional gel electrophoresis were
digested, and the peptides were subjected to MS analysis. A
trace yielded about 15–17matching peptidemasses, represent-
ing about 30–35% coverage for L-plastin (supplemental
Table S1, under () Bone). Peptide sequences identified in
MS are highlighted in red in supplemental Fig. S3A. A repre-
sentative mass spectrum (FSLVGIAGQDLNEGNR) is pro-
vided in supplemental Fig. S3B. Similarly, a trace yielded
about 25–31 matching peptide masses, representing about
19–22%coverage for cortactin (supplemental Table S1) in oste-
oclasts treated with bone particles (supplemental Table
S1, under () Bone).
Because there is a decrease in the level of L-plastin at 16–18
h, we extended this analysis to determine the L-plastin levels at
different time periods after the addition of bone particles in the
presence of RANKL andM-CSF. Immunoblotting with an anti-
body to L-plastin was performed with50g of lysate protein.
FIGURE 1. Analysis of actin distribution in osteoclasts subjected to bone
resorption.Osteoclasts plated on dentine slices for 3 h (A andA), 8 h (B), and
12 h (C) were stainedwith rhodamine-phalloidin to determine the changes in
thedistributionof actinduringbone resorption.Osteoclasts areoutlined inA
to indicate stretching off of membrane at 2–3 h. Actin aggregates that most
likely function as secondary adhesive structures are indicated by arrows in A.
An increase in the number of actin rings (B and C) was observed as a result of
the increased surface area of osteoclasts at 8 and 12 h. Scale bars, 25m. The
results are representative of four experiments with four separate osteoclast
preparations.
FIGURE 2. Analysis of cell shape changes in osteoclasts incubated with
native long bone particles. A, bone particles (60–80 m in size) isolated
from the long bones of mice. B, confluent osteoclast in culture prior to bone
treatment is shown. Osteoclasts were incubated with bone particles (60–80
msize) for 4 h (C) and 6 h (D). The arrowheads in C andD indicate osteoclasts
that are attached to bone particles. These osteoclasts are capable of forming
actin ring and bone resorption. Osteoclasts were viewed under a40 objec-
tive in an invertedmicroscope. Experimentswere repeatedwithmore than10
different osteoclast preparations. The data shown are representative of those
experiments.
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Immunoblotting of the same blot with an actin antibody after
stripping was used as a loading control. A decrease in the level
of L-plastin was observed from 8 h onward (Fig. 3B, lanes 3–6)
and remained unchanged until 20 h (lane 6). The decrease at
16–20 h correspondswith the decrease shown in Fig. 3A. These
results suggest that changes in the levels of L-plastin occur at
the early stage of bone resorption could be correlated with the
dynamic nature of the sealing ring.
Analysis of Protein Profile in Osteoclasts Incubatedwith
Different Substrates
Osteoclasts can attach to various substrates, such as glass,
synthetic mineralized materials (e.g. osteologic discs), and
mineralized bone (e.g. dentine, ivory, and natural bone). We
have used previously (1, 10, 11) and at this time biologically
derived hard tissues, such as devitalized native bone or den-
tine slices, as substrates for in vitro bone resorption assays.
Researchers also use osteologic discs containing submicron
calcium phosphate films (0.6 m) on transparent quartz
material (BD Biosciences) for in vitro bone resorption assays.
Therefore, we explored whether the aforesaid substrates are
biologically comparable and exhibit a very similar effect, as
shown in Figs. 1–3. We have observed migration of osteoclasts
toward native devitalized bone particles (Fig. 2C) and dentine
(supplemental Fig. S1) but not toward osteologic discs. There-
fore, osteoclasts were cultured on the surface of osteologic discs
and incubated in the presence of
RANKL (40–50 ng/ml) and M-CSF
(10 ng/ml) for 16–18 h. SDS-PAGE
was performed with lysates made
from osteoclasts treated with the
indicated substrates (Fig. 3C) for
16–18 h. Osteoclasts under the
same conditions as above but un-
treated with any of the indicated
substrates were used as controls
(Fig. 3C, lane 1). Although the ge-
ometry of bone and dentine surfaces
could be different, a very similar
protein profile was observed in
SDS-PAGE analysis (lanes 2 and 4).
However, the protein profile of
lysates made from osteoclasts incu-
bated on osteologic discs (lane 3)
does not correspondwith these pro-
files (lanes 2 and 4). Osteologic discs
lack bone matrix proteins and the
geometry of dentine or bone parti-
cles. It is possible that synthetic
mineralized matrices were quickly
resorbed by mature osteoclasts
within 4–6 h of incubation. We
have observed osteoclasts attached
on the quartz disc at this timeperiod
after the completion of resorption
of the calcium phosphate matrix
(data not shown). This could be the
possible reason for a relatively simi-
lar protein profile in osteoclasts untreated with bone particles
(lane 1) or plated on osteologic discs (lane 3).
Analysis of the Phosphoprotein Profile in Osteoclasts
Incubatedwith Bone Particles
Two-dimensional gel electrophoresis and MS analyses of
lysates made from osteoclasts incubated with bone particles
demonstrated peptides for a few of the proteins (Src kinase,
vacuolar H-ATPase B2, vacuolar ATP synthase catalytic sub-
unit A, L-plastin, cathepsin D and K, Arp2/3, cortactin, and
gelsolin) identified as being involved in bone resorption. In
order to gain insight into the signaling molecules involved in
osteoclast bone resorption in general, we looked at the phos-
phorylation state of proteins on tyrosine and serine residues.
We used250 g of lysate protein for immunoblotting analy-
ses (Fig. 3,D and E). Immunoblotting analysis with an antibody
to phosphotyrosine (Fig. 3C) displayed an increase in the phos-
phorylation of p130cas, cortactin, WASP, and c-Src in oste-
oclasts treated with bone particles. Minimal changes in the
tyrosine phosphorylation of PYK2were observed (Fig. 3D, lanes
1 and 2). This status might not exclude the role PYK2 in oste-
oclast function. Phosphorylationmayperhaps occur at the early
stage of maturation of the sealing ring from actin aggregates.
PYK2-dependent podosome belt formation in PYK2 null oste-
oclasts has been shown to occur by the kinase-defectivemutant.
It is also possible that PYK2 may function as a platform for
FIGURE 3. Analysis of the expression profile of proteins in osteoclasts treated with and without native
bone particles. A, treatments of osteoclasts with bone particles were performed as described under “Experi-
mental Procedures.” Lanes 1 and 2, lysate proteins made from osteoclasts incubated with () and without ()
boneparticles for 16–18hwere subjected to10%SDS-PAGEandCoomassieBlue staininganalyses. Lanes 3and
4, immunoblotting analysis with a cortactin (top) and L-plastin antibody (bottom). B, osteoclasts were treated
with bone particles for different time periods as indicated at the bottom. Lysates were separated on SDS-
polyacrylamide gels and then transferred and probedwith L-plastin and actin antibodies sequentially without
stripping.C, equal amountsof lysateproteins fromosteoclasts treatedas indicated in the figurewere subjected
to SDS-PAGE and Coomassie Blue staining. (), untreated osteoclasts; BP, bone particles;OD, osteologic discs;
DP, dentine particles. D, equal amounts of protein lysates made from osteoclasts treated with (lanes 2 and 4)
and without (lanes 1 and 3) bone particles were subjected to three SDS-10% polyacrylamide gels. Blots made
from these three gels were immunoblotted with anti-Tyr(P) (p-Tyrosine), p130cas, and PYK2 antibody, respec-
tively. These blots were stripped and blotted correspondinglywith GAPDH/cortactin,WASP, and Src antibody.
Immunoblotting of the first blot with GAPDH (37 kDa) and cortactin (80–85 kDa) antibody was performed
sequentiallywithout any further stripping. E, immunoblotting (IB) analysiswith aSer(P) (p-serine) antibody. This
immunoblot was sequentially probed with a Ser(P), L-plastin, and GAPDH antibody. Immunoblotting analysis
with a GAPDH (A, D, or E) or actin (B) antibody was used as a loading control. The results are representative of
three experiments performed with three separate osteoclast preparations.
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recruitment and assembly of signaling proteins besides its func-
tion as a kinase (37). An increase in the tyrosine phosphoryla-
tion of c-Src and cortactin (Fig. 3D, lanes 1 and 2) corresponds
with the protein levels in osteoclasts treated with bone par-
ticles (lanes 3 and 4). However, equal levels of WASP, PYK2,
and p130cas proteins were observed in osteoclasts untreated
and treated with bone particles (Fig. 3D, lanes 3 and 4). This
observation confirms the previous observations of ours and
others that an increase in the phosphorylation of several
signaling proteins is necessary for osteoclast bone resorption
(6, 7, 14, 18, 38).
Immunoblotting analysis with a phosphoserine antibody
showed a decrease in the phosphorylation state of L-plastin in
osteoclasts treated with bone particles (Fig. 3E, lane 2). This
corresponds with the decreased protein level of L-plastin (Fig.
3E, lane 4). Immunoblotting analysis with a GAPDH antibody
demonstrated the same levels of GAPDH protein (Fig. 3, A, D,
and E). Overall, these results demonstrate a decrease in L-plas-
tin and an increase in cortactin in osteoclasts incubated with
native bone particles for 16–18 h in the presence of RANKL
and M-CSF.
Analysis of the Effects of TNF- on the Protein Profile in
Osteoclasts Subjected to Bone Resorption
TNF- is sufficient to induce osteoclast differentiation
and bone resorption independently of the RANKL signaling
pathway (19, 20, 39–42). Chronic inflammatory bone dis-
eases, such as rheumatoid arthritis, periodontal disease,
and aseptic periprosthetic osteolysis are characterized by bone
loss around affected joints and teeth caused by increased oste-
oclastic bone resorption. This resorption is mediated largely by
the increased local production of TNF- (42). Therefore, we
checked whether TNF- could
induce effects similar to that of
RANKL in osteoclasts subjected to
bone resorption with bone particles
for the times indicated in Fig. 4 (A
and B). An equal amount (50 g)
of lysate protein made from oste-
oclasts incubated with () and
without () bone particles in the
presence of TNF- and M-CSF was
used. Immunoblotting analysis was
performed with L-plastin (Fig. 4A)
and cortactin (Fig. 4B) antibody.We
have observed a time-dependent
increase in L-plastin level at 2 and
4 h. A decrease was observed from
8 h onward, and the decrease was
stabilized until 12–20 h and then
increased at 24 h. Time-dependent
changes in the levels of L-plastin
protein correspond with the phos-
phorylation level of L-plastin on ser-
ine residues (data not shown). How-
ever, cortactin level remains the
same in osteoclasts untreated for
24 h (B, lane 1) and treated (lanes 2
and 3) with bone particles for 2 and 4 h. A gradual increase in
the level of cortactin was observed from 8 h onward, and this
increase was stabilized until 24 h.
As shown in Fig. 4, TNF- (Fig. 4C, lane 4) reproduced the
effects mediated by RANKL (lane 2) in the presence of bone
particles for 16–18 h. An increase in the levels of cortactin
with a corresponding decrease in L-plastin was observed
under these conditions (lanes 2 and 4) as compared with oste-
oclasts treated with M-CSF only in the presence of bone parti-
cles (lane 3) or both M-CSF and TNF- in the absence of bone
particles for 16–18 h (lane 1). Osteoclasts were pretreated with
an antibody to TNF- (lane 6) or TNF receptor (lane 7) for
60–90 min prior to the addition of bone particles, TNF-, and
M-CSF as described under “Experimental Procedures.” Oste-
oclasts treated as above with antibody failed to show a
decrease in L-plastin level. The level remains the same as in
control osteoclasts untreated with bone particles but treated
with TNF- and M-CSF (Fig. 4C, lane 1). However, a small
increase in the level of cortactin was observed in these cells
(lanes 6 and 7). Treatment of osteoclast with species-specific
IgG (lane 5) serves as a control for TNF- antibody treat-
ment (lane 6). The response to TNF- antibody was not
observed in osteoclasts treated with IgG. Thus, the failure of
anti-TNF-/TNFR1 treatment to alter L-plastin levels sug-
gests that TNF-/TNFR1 signals mediate the early phase of
sealing ring formation.
Analysis of the Effects of Bisphosphonates on the Protein
Profile in Osteoclasts Subjected to Bone Resorption
Bisphosphonates inhibit bone resorption by osteoclasts (43–
46). We recently reported that bisphosphonates could modu-
late the function of osteoclasts by inhibiting the tyrosine phos-
FIGURE 4. SDS-PAGE and immunoblotting analyses of lysates made from osteoclasts subjected to vari-
ous treatments. A and B, time-dependent effects of TNF- on L-plastin and cortactin levels. Equal amounts of
lysate proteins were used for immunoblotting analysis with an antibody (ab) to L-plastin (A) and cortactin (B).
Actin was used as a loading control in A and B. C, equal amounts of lysate proteins from osteoclasts treated as
indicated in the figurewere subjected to SDS-PAGE (10%) andCoomassie Blue staining analyses.MCSF, macro-
phage colony-stimulating factor; () and (), untreatedandboneparticle-treated; IgG, control nonspecific IgG
control; TNFR1, anti-TNF-1 receptor. D and E, equal amount of lysate proteins from osteoclasts treated with
various treatments, as indicated in the figure, were used for SDS-PAGE/Coomassie Blue staining (D) and immu-
noblotting analyses (E). Immunoblotting analyses with phosphocortactin (Tyr(P)421) (E, top, p-Cortactin), cor-
tactin (E,middle), andGAPDH (E,bottom) are shown. F–I, bone resorptionassay in vitro. Osteoclastswere treated
as indicated at the top of each panel (E–F). Pits were scanned under confocal microscopy. Resorption pits were
seen as dark spots. Scale bar, 25M. These results represent one of three separate experiments performedwith
the same results.
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phorylation of cortactin by regulating the activity of PTP-PEST
and Src kinase (10). Consistent with this observation, immuno-
blotting analysis with a phosphospecific antibody to cortactin
Tyr421 demonstrated a significant decrease in the Tyr(P)421
phosphorylation (Fig. 4E, top, lanes 3 and 4) and not the level of
cortactin in osteoclasts treated with alendronate (Al) and pam-
idronate (Pa) in the presence of bone particles, RANKL, and
M-CSF (Fig. 4E,middle, lanes 3 and 4). SDS-polyacrylamide gel
stained with Coomassie Blue corroborates this observation
(Fig. 4D, lanes 3 and 4).
Bone Resorption Assay in Vitro
Furthermore, we confirmed the stimulatory and inhibitory
effects of TNF- and alendronate on osteoclast bone resorption
in vitro (Fig. 4, F–I). The effects of RANKL (Fig. 4F) and TNF-
(Fig. 4H) on the stimulation of bone resorption activity of oste-
oclasts in vitro are blocked by alendronate (Fig. 4G) and anti-
TNF- (Fig. 4I), respectively. Taken together, these observa-
tions corroborate the role of TNF- in osteoclast function as
shown by others (39, 42). A decrease in the phosphorylation of
cortactin atTyr421 (Fig. 4E) and the presence of actin aggregates
in osteoclasts treated with alendronate (31) suggest that
bisphosphonates could modulate the function of osteoclasts by
inhibiting integrin v3 downstream signaling involved in
tyrosine phosphorylation of cortac-
tin (10). This could be separate from
the Rho GTPase pathway (44).
Analysis of Time-dependent
Changes in Actin Organization in
Osteoclasts Subjected to Bone
Resorption
The experiments shown in Figs.
3 and 4 indicate a clear association
of L-plastin and cortactin to oste-
oclast bone resorption. We sought
to determine the spatiotemporal
organization of L-plastin and cor-
tactin in osteoclasts plated on den-
tine slices by immunostaining and
confocal analyses (Fig. 5). It is
of particular interest to determine
whether the changes in the levels
and localization of L-plastin and
cortactin are in fact associated with
the reorganization of actin struc-
tures in resorbing osteoclasts. Im-
munostaining of osteoclasts plated
on dentine slices were performed
with L-plastin (Fig. 5, A–F) and
cortactin (Fig. 5, G–L). Costaining
with rhodamine-phalloidin was
performed to determine the actin
localization. Higher magnification
images of osteoclasts exhibiting
changes in actin organization are
shown. Changes in the actin distri-
bution were determined at different
time points in300 osteoclasts and provided as a graph in Fig.
5M. We have observed a spatiotemporal change in the sealing
ring organization and composition (i.e. localization of L-plastin
and cortactin) in a time-dependentmanner as described below.
L-Plastin/Actin Distribution—Besides diffuse distribution,
L-plastin localization was also observed as patches or aggre-
gates (indicated by arrowheads) within 1 h (Fig. 5A) of plating
mature osteoclasts on dentine. Colocalization of L-plastin
and actin was observed in some of these aggregates (indi-
cated by the arrows in Fig. 5, A and B). These aggregates
develop into larger sizes in a time-dependent manner from 2
to 4 h (Fig. 5, B and C). Multiple big and small actin aggre-
gates were observed at 4 h. Colocalization (yellow) of L-plas-
tin and actin was observed in these aggregates (Fig. 5C).
Actin aggregates fuse together by 6 h (Fig. 5D), at which time
localization of L-plastin in these structures is reduced, but
diffuse distribution of L-plastin was observed throughout
the osteoclast (Fig. 5D). A gradual decrease in the localiza-
tion of L-plastin (Fig. 5, E and F) accompanies cortactin
localization in actin aggregates and maturation of sealing
ring formation. Actin aggregate formation corroborates the
actin staining shown in Fig. 1. These data indicate that the
actin aggregates or patches are possible precursors or pre-
sealing zone for the mature sealing ring.
FIGURE 5. Confocal analysis of time-dependent changes in actin organization and localization of L-plastin
and cortactin in resorbing osteoclasts. A–L, confocal microscopic images of osteoclasts stained for actin (red),
L-plastin (green; A–F), and cortactin (green; G–L) are shown. Yellow color (indicated by arrows) represents the colo-
calization of proteins (A–C and H–J). M, changes in actin organization were determined in300 osteoclasts and
provided as a graph. Measurements were performed at the indicated time below the graph. Shown is basic actin
stainingwithnoactinpatchesor aggregates (APs),with actinpatchesor aggregates (APs),with small actin rings
(SARs), andwithmultiple or single bigmature actin rings (MARs). Data are provided asmean S.E. of three experi-
ments. **, p 0.001; *, p 0.05 versus cells with no actin patches.
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Cortactin/Actin Distribution in Sealing Ring—Distribution
of cortactin in actin aggregates is very minimal or not observed
at 4 h (Fig. 5G). Localization of cortactinwas observed from5 to
6 h onward (Fig. 5H) with a concomitant decrease in the local-
ization of L-plastin (Fig. 5D). An increase in the localization of
cortactin corresponds with the maturation of actin aggregates
to the sealing ring between 8 and
10 h (I and J). A gradual decrease in
the localization of cortactin was
observed from 12 h onward (K), and
at 14 h, cortactin was not observed
in the mature actin ring, although
diffuse distribution of cortactin
was observed in these cells (L).
The time-dependent changes in
actin organization in osteoclasts
expressing GFP-actin (supplemen-
tal Fig. S1) correspond with the
changes shown in fixed cells (Fig. 5).
Individual frames of the osteoclasts
at 2–4, 4–6, and 10–12 h time peri-
ods are shown. Actin aggregates
were formed at 4–6 h, and matura-
tion of actin aggregates into a func-
tional sealing ring was observed at
10–12 h (supplemental Fig. S1, SR
in C). Cells spread well on the bone
at this time (supplemental Fig. S1C),
and a resorption pit (supplemental
Fig. S1, 2 in C) was found under-
neath the sealing ring (supple-
mental Fig. S1C).
Analysis of the Role of Cortactin in
Sealing Ring Formation and Bone
Resorption
To address the possible role
of cortactin in the maturation of
actin aggregates to sealing ring, we
knocked down or depleted cortactin
using siRNA sequences. Untreated
(Fig. 6I, A, lane 1) and scrambled
RNAi (ScRNAi)-treated osteoclasts
were used as controls. Osteoclasts
were incubated with siRNA (A,
lanes 3 and 4) or ScRNAi (lane 2) for
18–20 h at the indicated doses as
described previously (7). A dose-de-
pendent decrease in the cortactin
level was observed in osteoclasts
treated with siRNA to cortactin and
incubated for 16–18 h at 37 °C (A,
lanes 3 and 4). The decrease was
maximal at 200 nM siRNA (90–
95%; lane 4) as compared with the
levels of protein in ScRNAi-trans-
fected osteoclasts (A, lane 2). The
viability of osteoclasts was tested by
a trypan blue exclusion test. Immunoblotting with a GAPDH
antibody was used as a loading control (Fig. 6I, B).
After transfection with siRNA and ScRNAi for 18–20 h,
osteoclasts were cultured on dentine slices for 10–12 h.
Osteoclasts transfected with ScRNAi displayed mature seal-
ing rings (Fig. 6II, A and D). Localization of cortactin (6II, A)
FIGURE 6. Analysis of the effects of depletion or knockdown of cortactin on sealing ring formation and
bone resorption. I, immunoblotting analysis of cortactin levels in osteoclasts treated with control RNAi (Sc;
200 nM) and siRNA (Si; 100 and 200 nM) to cortactin (A). Immunoblotting analysis with GAPDH is shown in B. II,
the effects of ScRNAi (A and D) and siRNA (B, C, and E) to cortactin on sealing ring formation. Osteoclasts were
stained for cortactin (green) and actin (red). Cortactin distribution is shown in A–C. The effects of scrambled
RNAi and SiRNA on multiple osteoclasts are shown in D and E. Osteoclasts were stained for actin (red) with
rhodamine-phalloidin. Dentine is shown by the reflected light (green in D and E). Resorption pits were found
underneath osteoclasts (D, D, E, and E). Actin distribution (D and E) and resorption lacuna (D and E) are
shown separately in gray. Actin aggregates and superficial pits are indicated by asterisks in E and E. Sealing
rings are indicated by arrowheads (D and D) and arrows (E and E). Scale bar, 25 m. III, bone resorption assay
in vitro. Osteoclasts treated with scrambled ScRNAi and siRNA were cultured on dentine for 24 h. Pits were
scanned in a confocal microscopy. Resorption pits were seen as dark spots. Experiments were repeated three
times with three different osteoclast preparations. These results represent one of three separate experiments
performed with the same results.
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and actin (A) was observed in the sealing ring of resorbing
osteoclasts. The in vitro bone resorption assay displayed an
increase in the pit area or complexity with untreated and
scrambled RNAi-treated osteoclasts (Fig. 6III, A and B). A
significant decrease in the staining of cortactin was observed
in a dose-dependent manner in siRNA to cortactin-treated
cells (Fig. 6II, B and C). The effects of scrambled RNAi and
siRNA on multiple osteoclasts are shown (Fig. 6II, D and E).
Osteoclasts transfected with siRNA to cortactin displayed
either small actin rings (indicated
by arrows in Fig. 6II, E and E) or
actin aggregates (Fig. 6II, B and
C; indicated by asterisks in E). A
decrease in bone resorption in
vitrowas observed (Fig. 6II, E) in a
dose-dependent manner (Fig. 6III,
C and D). The presence of actin
aggregates and the failure of seal-
ing ring formation in siRNA-
treated cells suggest that cortac-
tin-mediated actin polymerization
is involved in the maturation of
the sealing ring.
Localization of Integrin3 in
Sealing Ring
L-plastin phosphorylation has been
shown to associate with integrin acti-
vation (47). Osteoclasts cultured on
dentine slices for 12–14 h were pro-
cessed for double staining with
actin/cortactin (Fig. 7, A and B) and
actin/integrin 3 (Fig. 7C). Diffuse
colocalization of actin with cortac-
tin (Fig. 7A) and integrin (Fig. 7C)
was observed in resorbing oste-
oclasts. Osteoclasts are capable of
organizing two to four sealing rings
during bone resorption (Figs. 1 and
6) (11). We thought that a group or
linear series of resorption pits were
formed by sequential processes of
resorption, motility, and adhesion
of osteoclasts along the surface of
dentine or bone. The results shown
in Fig. 7I (A and C) also suggest
that a multinucleated giant oste-
oclast can orchestrate sealing rings
in greater number (i.e. 6–8 at a
time) (Fig. 7I, B, B, and C), which
leads to the formation of a group of
resorption pits underneath the oste-
oclast (Fig. 7I, A and C). Oste-
oclasts exhibiting either single (Fig.
7I, C, arrowhead) or multiple (Fig.
7I, A, B, and C) sealing or actin
rings during bone resorption were
observed. The osteoclast, which is
indicated by an arrow (Fig. 7I, A), is shown at higher magni-
fication in Fig. 7I, B and B. Colocalization of actin with
cortactin was observed in patches in a confocal microscopy
scan of the osteoclast taken at the level of dentine (Fig. 7I, B
and B). More than eight actin rings (outlined in Fig. 7I, B)
were observed in this osteoclast. The sealing rings formed
were efficient and functional, which is recognized from the
matching resorption pit underneath the osteoclast (indi-
cated by an asterisk in Fig. 7I, B, B, and C).
FIGURE 7. I, confocal analysis of localization of actin with cortactin and integrin 3. Osteoclasts cultured on
dentine slices for 12–14 h were processed for double staining with actin/cortactin (I, A and B) and actin/
integrin 3 (C). Confocal microscopic images of osteoclasts stained for actin (A–C, red), cortactin (A,
green), and integrin 3 (C, green) are shown. Yellow color represents colocalization of cortactin and
integrin 3 with actin (overlay panels A and C). A higher magnification view of the area indicated by an
arrow in A is shown in B and B. More than eight actin rings (outlined in B) were observed in this
osteoclast. Resorption pits are indicated by asterisks, and an osteoclast that exhibits single or multiple
sealing rings is indicated by an arrowhead (A, C, and C). Scale bars, 10 m (B) and 25 m (C). II, confocal
analysis of localization of actin with cortactin, integrin 3, and L-plastin in osteoclasts treated with siRNA
and ScRNAi to cortactin. Osteoclasts were treated with ScRNAi (A) and siRNA to cortactin (B and C).
Confocal microscopic images of osteoclasts stained for actin (A–C, red), cortactin (A, green), integrin 3 (B,
green), and L-plastin (C, green) are shown. Yellow color represents colocalization of cortactin and integrin
3 with actin (overlay panels A and B). Scale bar, 25 m. The results represent one of the three separate
experiments performed with three different osteoclast preparations.
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The Effect of Cortactin Depletion on the Formation of Sealing
Ring
After treatingwith ScRNAi (Fig. 7II,A) and siRNA (Fig. 7II,B
and C) to cortactin for 18–20 h, osteoclasts were cultured on
dentine slices for 8–12 h. Cells were double-stained for actin/
cortactin, actin/integrin 3, and actin/L-plastin. Osteoclasts
transfected with ScRNAi displayed colocalization of actin and
cortactin in sealing rings (7II, A). As shown in Fig. 6, actin
aggregates were found in osteoclasts transfected with siRNA to
cortactin (Fig. 7II, B and C). These actin aggregates demon-
strated colocalization of integrin 3 (Fig. 7II, B) but not L-plas-
tin (Fig. 7II, C). L-plastin staining was observed throughout the
osteoclasts but at a very minimal level. The reduced staining
correspondswith the reduced L-plastin levels at 8–20 h in oste-
oclasts incubated with bone particles for 4–20 h (Fig. 3B). Fail-
ure ofmaturation of the sealing ring in cortactin-depleted oste-
oclasts (Fig. 6) despite the localization of integrin v (data not
shown) and 3 in actin aggregates (Fig. 7II, B) suggests that the
maturation process is dependent on cortactin. Other actin-
binding protein(s) could not recompense its role in the matu-
ration process.
Analysis of Actin Distribution in Response to Treatment with
TNF-
Several studies report interesting outcomes for the role of
TNF- in osteoclast differentiation and function (24, 25, 39, 48,
49). Cyclical changes in L-plastin and cortactin protein levels
were observed in a time-dependent manner (Fig. 4, A and B).
Next, we proceeded to determine if TNF- could reproduce the
effects mediated by RANKL in the chronological processes of
organization of the mature sealing ring. Therefore, osteoclast
precursors were cultured on top of dentine slices and incubated
for 2–3 h at 37 °C for adhesion. After adhesion for 2–3 h, cells
were replaced with fresh medium containing TNF- and
M-CSF, and incubation at 37 °C was continued for 4, 8, and
12 h. Cells were fixed and stainedwith rhodamine-phalloidin to
determine the distribution of actin. Consistent with previous
studies (24), we have shown here that TNF- has a role in oste-
oclast sealing ring formation during bone resorption. We have
observed time- dependent changes in the organization of actin
filaments. TNF- treatment simulates the formation of actin
aggregates at 3–4 h (Fig. 8I, A). Between 8 and 10 h, the size of
actin aggregates increased in addition to the formation of some
actin rings. Osteoclasts spread well and form multiple actin or
sealing rings at 12–14 h (Fig. 8I,C). Actin rings (indicated by the
arrowheads in Fig. 8I,B andC) formed at 8 h (B) and 12 h (C) are
capable of resorbing bone, and pits were found underneath the
sealing ring (green panels in B and C). TNF- (Fig. 4C) repro-
duced the effects mediated by RANKL in changes in the levels
of L-plastin and cortactin (Fig. 4C) as well as organization of the
sealing ring in a time-dependent manner.
FIGURE 8. I, confocal analysis of time-dependent changes in actin organiza-
tion andbone resorption in response to TNF-. Osteoclasts plated ondentine
slices were treated with TNF- for 2–3 h (A), 8 h (B), and 12 h (C). Confocal
microscopic images of osteoclasts stained for actin are shown. Distribution of
actin (red) and scans of dentine slices (green) are shown separately. Several
resorptionpitswere observed after incubationwith TNF- for 12–14h. II, con-
focal analysis of the effects of various treatments on sealing ring formation
and bone resorption. Osteoclasts were treated with a neutralizing antibody
to TNF- (B), Src (C), andv inhibitor (D) in the presence of TNF-. Osteoclasts
treated together with a species-specific IgG and TNF- were used as con-
trol (A) for neutralizing antibody to TNF- antibody treatment (B). Sealing
rings are indicated by arrowheads in A. Punctate podosome-like struc-
tures are indicated by crooked arrows in B and C (red panel). Actin patches
(B and C, red panel) and aggregates are indicated by arrows (D, red panel).
Bone resorption is considerably reduced in osteoclasts treated with a neu-
tralizing antibody to TNF- (B) and inhibitors to Src and v (C and D) in the
presence of TNF- (green panels). Scale bar, 25 M. The results represent
one of the three separate experiments performed with three different
osteoclast preparations.
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Studies with anti-TNF- and anti-TNFR1 suggest that
TNFR1 can elicit signals related to the formation of actin aggre-
gates because osteoclasts treated with these antibodies failed to
show changes in the levels of L-plastin (Fig. 4C, lanes 6 and 7).
Therefore, to further elucidate the possible role of TNF- sig-
naling in osteoclast cytoskeletal reorganization during bone
resorption, osteoclasts were treated with the neutralizing anti-
body to TNF- (Fig. 8II, B), Src inhibitor (Fig. 8II, C), and v
inhibitor (Fig. 8II, D) plus TNF- for 12–16 h. Osteoclasts
treatedwith a species-specific non-immune IgG in the presence
of TNF- were used as a control (Fig. 8II, A) for the antibody
treatment shown in Fig. 8II, B. Osteoclasts were stained for
actin with rhodamine-phalloidin (Fig. 8II). Consistent with the
observation shown in Fig. 8I, C, TNF- not only increased the
spreading of osteoclasts but also the formation of several seal-
ing rings in one osteoclast. Nonspecific IgG had no effect on the
changes elicited by TNF-  (Fig. 8II, A).
A neutralizing antibody to TNF-, Src inhibitor, and v
inhibitor reduced the effects of TNF- at different levels. These
osteoclasts displayed a considerable decrease in bone resorp-
tion (Fig. 8II,B–D, green panel). Osteoclasts treated with a neu-
tralizing antibody to TNF- (Fig. 8II, B) and an Src inhibitor
(8II, C) in the presence of TNF- demonstrate comparable
effects. Under both conditions, punctate and small patchy actin
structures were observed in these osteoclasts (B and C). Punc-
tate structures resemble podosomes and are distributed
throughout the osteoclasts and at the periphery (8II, B and C;
indicated by crooked arrows). Actin patch-like structures are
smaller in size. Therefore, both podosome- and actin patch-like
structuresmay compromise cell adhesion on bone but not actin
aggregate or sealing ring formation. TNF- signaling might be
essential for the disassembly of podosomes and formation of
actin aggregates. It is possible that Src may be part of a TNF--
activated signaling pathway. In contrast, osteoclast treatedwith
v inhibitor exhibited actin aggregates in the presence of
TNF- and M-CSF. v inhibitor indeed reduced the matura-
tion of actin aggregates to the sealing ring. Therefore, bone
resorption is considerably reduced in these osteoclasts (Fig. 8II,
D, green). The presence of actin aggregates (8II, D, red; indi-
cated by arrows) in these osteoclasts suggests that it occurs
upstream and also independent of integrin signaling. Forma-
tion of actin aggregates in osteoclasts treatedwith av inhibitor
suggests that the maturation of the sealing ring is under the
aegis of integrin v3 signaling.
DISCUSSION
There is a linear correlation between the size of the oste-
oclasts and the number of nucleus (50). The area of the resorp-
tion pit formed by each osteoclast can be correlated with the
number of nuclei and size of the osteoclast. This is because
thosemultinucleated giant osteoclasts can cover a large area on
the bone and consequently form big resorption pits (51). Big
osteoclasts make multiple contacts by membrane extension
and demonstratedmarginal or peripheral crawling, as shown in
this paper (Figs. 1 and 5–8). Therefore, they are capable of
forming multiple sealing rings, which resulted in the formation
of multilocular pits (Figs. 4 and 6–8). Small osteoclasts are
capable of making either simple (single) pits or contiguous pits
linearly (Fig. 7C, indicated by an arrowhead) (32). The latter is
due to sequential events of cell adhesion, resorption, andmigra-
tion of osteoclasts in one direction. It is not known whether an
osteoclast can make multiple sealing rings during bone resorp-
tion in vivo. However, it is likely, based on time lapse live anal-
yses performed by several investigators, including our own
using various mineralized matrices, such as dentine
(supplemental Fig. S1) and bone slices (52) as well as discs
coated with apatitecollagen complexes (53, 54).
In an early study, osteoclasts have been shown to develop
different patterns of contact characteristics, such as rings, cres-
cents, and patches. Formation of these structures reflects the
progress of the cell in the process of bone resorption. Oste-
oclasts are uniquely motile in that they continue to resorb bone
beneath one area of the cell while another area is moving and
reorganizing a sealing ring (55). Our study also shows that oste-
oclasts make actin aggregates or patches during the extension
of themembrane. These secondary actin adhesive aggregates or
patches confer extensive adherence anduniquemotile behavior
as well as membrane extension (Figs. 7 and 8). These are con-
sistent with the observations shown by others in the formation
of actin-rich adhesion structures prior to the formation of the
sealing ring (52). These actin aggregates may function as sec-
ondary adhesive structures and assist in the spreading of oste-
oclasts (Fig. 1,A–C). The spreading of osteoclasts with traction
by the secondary actin adhesive structures increases the surface
area. This may also possibly decrease the distance between
osteoclasts and bone to facilitate proximity of ruffled border to
bone. Actin aggregate formation seems to be necessary for the
ensuing development of the sealing ring (Figs. 5–8) regardless
of the number of sealing rings. Actin aggregateswere 8–10-fold
larger (Figs. 1 and 5–8) than podosome- or actin patch-like
structures observed in osteoclasts treated with a neutralizing
antibody to TNF- (Fig. 8II, B and C). We consider that these
actin aggregates or patches may be precursors for the sealing
ring.
It is generally thought that the sealing ring is derived from the
fusion of podosomes (14, 56, 57). However, several findings
suggest that the sealing ring on bone has a different three-di-
mensional organization not derived from podosomes. The spa-
tial arrangement of the presealing zone (referred to as actin
aggregates) demonstrated neither clusters nor rosettes of podo-
somes. We found that osteoclasts plated on gelatin substrate (a
non-mineralized matrix) organize either rosettes or clusters of
podosomes at the migration front. These podosomes were ca-
pable of degrading the gelatin matrix because of the presence
of MMP9 in these structures (36). Also, degradation of the
matrix underneath the osteoclasts was not observed. These
structures are different from typical podosome structures that
are observed in osteoclasts during adhesion and migration (1,
36). Based on the time-dependent analysis (Fig. 5) and previous
reports of others (53, 58), we suggest that sealing rings may not
be the derivative of podosomes. We suggest this based on our
previous observations in osteoclasts generated from gelsolin
null (Gsn/) mice. A dearth of gelsolin blocks podosome
assembly and motility but not sealing ring formation and bone
resorption (1). The resorbed areas by these osteoclasts are sim-
ple and non-contiguous due to the hypomotile nature of oste-
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oclasts (1). Observations in Gsn/ OCs also suggest that the
organization of the sealing ring necessitates the role(s) of dif-
ferent actin-regulatory proteins.
We have observed time- dependent changes in the levels
of L-plastin and cortactin in osteoclasts subjected to bone
resorption (Figs. 2–4). It is interesting to speculate that actin
aggregates are formed by L-plastin due to its actin bundling
property (Fig. 5). This occurs at the early phase of bone
resorption. Actin aggregates may function as an assembly cen-
ter in the localization of integrin and other signaling molecules
that are critical in the maturation of actin aggregates to func-
tional sealing rings. L-plastin was described to be homologous
with the F-actin-bundling protein fimbrin (59), and it is present
in the podosomes of osteoclasts (2, 60). However, its function in
osteoclasts is highly unknown. Analysis in L-plastin null oste-
oclasts (LPL/) demonstrated normal osteoclast differentia-
tion and peripheral podosomes. However, significant decreases
in the formation of the adhesive contact region (actin aggre-
gates) reduces not only the functional sealing ring formation
but also the membrane extension or marginal unique motile
quality (data not shown). Our results provide the first evidence
of the role of L-plastin in the formation of actin aggregates in
osteoclasts.
Cortactin is an important substrate for Src kinase (61). Cor-
tactin has been implicated in osteoclast podosome assembly/
disassembly and bone resorption (6, 10, 62, 64). siRNA to cor-
tactin blocked sealing ring formation, but these osteoclasts
displayed actin aggregates (Figs. 6 and 7II). Although siRNA to
cortactin inhibits the maturation of the sealing ring, it had no
effect on the function of L-plastin, formation of actin aggre-
gates (Figs. 6 and 7II), and localization of integrinv3 (Fig. 7II,
B). Taken together, these data suggest that cortactin-mediated
actin polymerization occurs at the later stage of sealing ring
formation. The roles of several signalingmolecules and integrin
signaling in the formation of the sealing ring are currently iden-
tified. However, the role of integrin signaling in the maturation
of the sealing ring has not been studiedwell. Phosphorylation of
L-plastin on serine residues is associated with the integrin acti-
vation (65). Localization of integrin v3 (Fig. 7, I and II) in the
actin aggregates may play a role in the maturation of actin
aggregates to the sealing ring.
Up-regulation of signaling proteins, such as c-Src, Rho, Rho
kinase, and cortactin, was observed in osteoclasts subjected to
bone resorption (Fig. 3, supplemental Fig. S2, and supple-
mental Table S1). Interestingly, osteoclasts subjected to the fol-
lowing treatments blocked maturation of the sealing ring and
bone resorption but displayed actin aggregates. The treatments
are: echistatin (66); bisphosphonates (31); v inhibitor (Fig. 8);
phenyl arsine oxide (an inhibitor to PTP-PEST) (10); and
siRNA to cortactin (Fig. 6) (6), PTP-PEST, or WASP (7, 10).
Consistent with our observations, WASP null osteoclasts also
demonstrated actin patches and reduced bone resorption (8).
Integrin3 (Fig. 7II),WASP, and Src localize to the actin aggre-
gates of osteoclasts treated with siRNA to cortactin (Fig. 7II) or
PTP-PEST (7) and bisphosphonates (10). The failure of forma-
tion of mature sealing ring in these osteoclasts suggests differ-
ent levels of defective downstream integrin signaling mecha-
nism. Cortactin integrates signals from Src kinase to form a
trimolecular complex (cortactinWASPArp2/3), which acti-
vates actin polymerization (67–69). Reducing the levels of
either one of the proteins seems to have an impact on osteoclast
bone resorption (8).
The comparable actin staining in osteoclasts treated with Src
inhibitor and neutralizing antibody to TNF- suggests that Src
also functions (Fig. 8) at the early stage of sealing ring formation
(i.e. organization of the presealing zone or actin aggregates) in a
TNF--dependentmanner. There is clear evidence that human
and mouse TNF- stimulated the expression of c-Src in oste-
oclasts (70). Furthermore, we have shown previously a diffuse
distribution of actin in osteoclasts expressing kinase-defective
(KD) Src in the presence of RANKL. Neither podosomes nor
actin aggregates were found in these osteoclasts (7). These
observations raise the following questions. Does TNF- regu-
late disassembly or turnover of podosomes and RANKL regu-
late the assembly of actin aggregates in osteoclasts? Does Src
have a role at the early and late phase of sealing ring formation?
Activation of Src by different signaling pathway may lead to
varied downstream activation mechanisms and functional out-
comes at the early and late phase of the sealing ring. As sug-
gested by others, TNF- could synergize with RANKL to
increase osteoclast activation to a large extent (24). It is possible
that the TNF-/RANKL pathway could occur at the initial
phase of sealing ring formation followed by the activation of
integrin v3 signaling toward the maturation phase of the
sealing ring. The role of TNF- and RANKL-mediated path-
ways and the exact step in which Src kinase fits in this pathway
to regulate the formation of actin aggregates via L-plastin
remain to be determined.
Inhibition of integrin v3 signaling with a v inhibitor or
knockdown of 3 integrin with an siRNA (data not shown) had
negligible effect on either the phosphorylation of L-plastin at
the serine 9 residue or the formation of actin aggregates. Treat-
ment of osteoclasts with a v inhibitor did not block the local-
ization of integrin in actin aggregates. However, localization of
Src and cortactin in actin aggregates was blocked. Therefore,
these osteoclasts demonstrated defective downstream signal-
ing. Integrin expression and ligand binding affinity were not
changed in Src/ osteoclasts despite the consequences of
defective downstream signaling (71). Integrin 3 knock-out
mice displayed an osteosclerotic phenotype, suggesting that
osteoclast activity is not completely affected (72). However, tar-
geted disruption of Src leads to the osteopetrotic phenotype
due to a defect in the activity of osteoclasts (73). This possibly
suggests a multiplicity of roles for Src at different levels in oste-
oclast function, including (a) assembly/disassembly of podo-
somes for adhesion andmigration; (b) formation of actin aggre-
gates, which function as a center for orchestrating integrin
signaling; and (c) maturation of actin aggregates to fully func-
tional sealing ring.
Bone consists of organic (collagen and a variety of non-col-
lagenous proteins) and inorganic components. Surface micro-
geometry of implants plays a role in tissue/cell-implant surface
interactions. However, our understanding of its effects at cellu-
lar levels or responses of bone cells to implants is incomplete.
Podosomes were observed in cells plated on glass coverslips.
Either actin aggregates or sealing rings were found in osteoclast
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cultures on apatite crystals (53), dentine (10, 11), or human
bone sections (data not shown). Formation of an actin-rich
sealing ring may depend on minerals present in the bone.
Therefore, osteoclasts were incubated with non-demineralized
(native bone) and demineralized bone particles for 16–18 h.
Live cell imaging at 4–6 h and 12 h demonstrated that oste-
oclastsmigrated toward and adhered to the demineralized bone
particles (supplemental Fig. S5A). However, the failure of
changes in the levels of cortactin in SDS-PAGE analysis in
lysates made from osteoclasts treated with demineralized bone
particles suggests that bone particles having mineral a crystal
structure are resorbable by osteoclasts and physiologically well
suited for the signaling mechanism orchestrated by integrin
v3 (supplemental Fig. S5B). Cortactin controls osteoclastic
bone resorption by regulating actin organization (64) (Figs.
5–7). Osteoclasts are able to adhere (supplemental Fig. S5A)
and resorb the organic phase of bone. It may occur by a process
localized to the attachment site of osteoclasts by protease activ-
ity (74) independent of sealing zone formation.
Commercial cortical crushed bones have been used as
allografts for several purposes, including filling of bones to
evade bone defects. Demineralized freeze-dried bone allografts
have been used extensively for periodontal therapy to induce
bone formation in human extraction sockets. Bone formation is
the principle process in peri-implant healing. This occurs by
migration and localization of bone cells in the area of implants,
differentiation of bone cells (osteoblasts and osteoclasts), and
bone resorption followed by bone formation. Biopsies from six
of the seven grafted sites were evaluated for new bone forma-
tion. Demineralized freeze-dried bone allograft sites revealed
the presence of dead particles of demineralized freeze-dried
bone allografts with no evidence of bone formation on the sur-
faces of the implanted particles and no evidence of osteoclastic
resorption of the bone particles (63, 75). Our in vitro observa-
tions indeed suggest that the organic phase of the bone is essen-
tial for the recruitment of bone cells. However, mineralized
matrix is required for the bone resorption function of oste-
oclasts. We suggest that graft materials with a combination of
organic and inorganic components besides bone substitute
material or biocompatible polymer may support good remod-
eling process.
CONCLUSIONS
Our aim is to dissect the molecular mechanisms behind the
cyclical processes of sealing ring formation. Taken together,
our results suggest that TNF-, RANKL, and integrin v3-
mediated pathways play roles in sealing ring formation and
bone resorption. L-plastin has a role in the earliest stages of
sealing ring formation. Phosphorylation of L-plastin and its
activation occur independently of integrin v3 signaling (data
not shown). Src kinase may play a role in the formation of actin
aggregates through the TNF-/RANKL pathway. The TNF-/
RANKL pathway could occur at the initial phase of sealing ring
formation, subsequently followed by the activation of integrin
v3 signaling toward thematuration phase of the sealing ring.
Although integrin signaling has been shown to play a role in the
formation of the sealing ring, its role in the maturation of actin
aggregate to sealing ring has not yet been studied. The presence
of actin aggregates in osteoclasts treated with v inhibitor,
siRNA to cortactin, Src inhibitor, and bisphosphonates (which
block PTP-PEST and Rho GTPase activity) suggests that the
formation of actin aggregates occurs independently of these
molecules. Src kinase plays a crucial role at each level. A novel
mechanistic link between plastin and cortactin localization and
function exists in sealing ring formation. The formation of a
spatially and dynamically regulated functional sealing ring and
optimal bone resorptive capacity relies on the integrin-depen-
dent pathway, which may involve the formation of the trimo-
lecular complex consisting of cortactinWASPArp2/3.
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SUPPLEMENTAL DATA  
EXPERIMENTAL PROCEDURES 
Two dimensional gel electrophoresis (2DGE) —About 300-500 μg protein was used for 2DGE. The 300 
microgram of soluble  protein mixture was initially rehydrated  using 4-7  pI  IPG strip (GE health care,  
USA) in rehydration solution with a composition of 8M urea, 4% CHAPS, 7mg DTT per 2.5 ml of 
rehydration buffer with 2% 4-7 IPG buffer (GE healthcare, USA). The rehydrated IPG strips were 
subjected to isoelectric focusing employing Electrophoretic IQ (Proteome system, USA) with an initial 
gradient voltage accumulation (10000V) in 8 hours followed by 16 hours holding at 10000V. The focused 
strips were used for 2DGE employing Electrophoretic IQ gel running apparatus (Proteome system USA) 
at a constant current of 30mA/gel for 120 min.  The gels were stained with silver stain (Invitrogen USA). 
For visualization of protein, images were captured using Alpha Innotech image scanner (Alpha Innotech 
Corporation, USA). Global protein expression differences of the treated and untreated sample gels were 
compared using Z3 image analysis software (Compiegne, Israel). 
Mass spectrometry— The selected spots/bands from the gels were initially trypsinized overnight at 370C 
using standard protocol after DDT reduction and Iodoacetamide alkylation. LC- MS analysis of tryptic 
peptides derived from protein samples was performed on Thermo finnigan LCQ XL mass spectrometer 
(Thermo Finnigan USA) which was connected to nanospray ionizer. The Surveyor chromatographic 
system with auto sampler (Thermo Finnigan, USA) was used for peptide separation. The LC system was 
connected to 10.5 cm fused silica reverse phase C18 column (Pico frit column, New Objective, USA).  
The peptides were separated during 90 minute linear gradient of 5-90% acetonitrile/water mixture, 
containing 0.1% formic acid at a flow rate of 300 nanolitre/min. The spectrums were accumulated and the 
acquired MS scans were searched against the mouse protein data base (IPI) using SORCERER search 
algorithm. The best hit was selected based on probability / percent of coverage and number of peptides. 
Expression of GFP actin in osteoclasts and confocal microcopy analysis of localization of G-actin in live 
cells— Osteoclasts were transfected with human ß-actin containing an NH2-terminal EGFP vector 
(Clonetech) using MIRUS reagent (Cat. No. MIR 2804). Expression of GFP-actin was confirmed at 10-12 
h after transfection with an inverted microscope. Dentine slices were added to osteoclast cultures and 
images were acquired at 2-3h (Figure S3-A), 4-6h (S3-B), and 10-12h (3S-C) with a 1.4 NA Plan Apo 
63x objective (Bio-Rad confocal microscopy). GFP was excited using a 488-nm laser line.  
Real-time RT-PCR Analysis— Total RNA was extracted from osteoclast treated with bone for different 
time periods using Qiagen RNeasy mini kit protocol with the DNase digest (Qiagen). Reverse 
transcription reaction was performed in a 20μl-reaction volume with 1 μg of total RNA by following the 
instructions provided by the manufacturer (Invitrogen, Carlsbad, CA). The cDNA was stored at -200C 
until further use. For real time PCR, primers were designed by Primer Express software (Applied 
Biosystems Group). A total of 15 primer pairs (Table S2) were designed with amplification product 
length of 100–200 bp and annealing temperature of ~60 °C. 18s rRNA and GAPDH were used 
for normalization. About 600-900nM of each primer was used.  Each reaction was performed in 
duplicates or triplicates in 25 μl volume in 96-well plates with a SYBR green reaction mix (Applied 
Biosystems Group) in an ABI 7000HT thermocycler (2 min at 50 °C, 10 min at 95 °C and 40 cycles 
of 15 s at 94 °C and 1 min at 60 °C). The expression was calculated relative to that of untreated control 
cells and normalized for 18S rRNA measured under the same conditions with Taq Man ribosomal RNA 
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control primers (Applied Biosystems/Roche, Branchburg, NJ), using the 2–∆∆CT method {Livak, 2001 
6908 /id}.   
 
RESULTS 
Analysis of time-dependent changes in actin organization in osteoclasts subjected to migration towards 
dentine slices— Depending on the substratum upon which the osteoclasts are spread, there are two 
different structures of actin known as podosomes and the sealing zone. To understand the specific 
properties and relationship of podosomes and the sealing zone, we used live-cell imaging of cultured 
osteoclasts. Osteoclasts migrated towards dentine particles (Figure S1, indicated by arrow heads in A and 
C). Osteoclasts attached to the edges of dentine particles at 2-3h (A) and at this time, punctate distribution 
of actin was observed in the cytoplasm (Figure S3A and A’). Organization of actin-rich basolateral 
membrane-like structure occurs right opposite to the attachment zone to bone (indicated by asterisks in 
A’). At 4-6h, punctate actin structures were converted into peripheral plasma membrane-like structure 
(Figure S3, B). Actin aggregate (indicated by a wavy arrow in B’) was observed at the attachment site to 
bone (B and B’). We believe that the actin aggregate is a precursor for a sealing ring (SR). At 10-12h (C), 
maturation of this actin aggregate into sealing ring (SR in C’) was observed. Resorption pit (#2 in C”) 
was found underside of the sealing ring (C). Two resorption pits were found adjacent to each other (#1 
and #2 in panel C”). Single osteoclast is capable of forming multiple sealing rings during bone resorption 
(Fig.1B and C and ref. {Ma, 2008 7106 /id}). Extension of osteoclast membrane near resorption pit #1 
suggests that both pits may perhaps be generated by the same osteoclast but at different time. It is also 
possible that the actin clumps observed near the resorption pit (#1 in C’’) may be part of the disassembled 
sealing ring (DSR in C’).  
Analysis of cell lysates by two dimensional gel  electrophoresis— To analyze the expression profile of 
proteins, we have first performed two-dimensional (2-D) gel electrophoresis (GE) using lysates (500μg) 
made from osteoclasts treated with (+) or without (-) bone particles (Figure S2). A representative 2-D gel 
stained with silver stain is shown in this figure. Gels were scanned using the image processing software 
(Z3, Compugen) to determine expression differences between the same spot of different gels. 
Approximately 200-250 protein spots could be detected in the 2D gels (Fig.5). The molecular masses of 
the intracellular proteins were distributed in the range of 25 kDa–150 kDa and isoelectric points of 4.0–
7.0. About 18 unique, 12 down-regulated and 21 up-regulated spots were identified by Z3 analysis. Spots 
that show significant changes are indicated in the figure. Some of the proteins that are indicated by circles 
in untreated osteoclasts are down-regulated in osteoclasts treated with bone particles (B). A few of the up-
regulated proteins are indicated by arrows in B.  
Mass spectrometry analysis of protein spots after digestion with trypsin— The protein spots that 
demonstrated a significant change (p<0.001) in abundance between the protein fractions of osteoclasts 
untreated (-) and treated (+) with bone were selected for further characterization using mass spectrometry 
(MS). For example, spots (# 1 and 2 in Figure S1) were physically cut out from the gel and digested with 
trypsin to analyze by MS. A representative mass spectrum of one of the peptides 
(FSLVGIAGQDLNEGNR-highlighted in green) is provided (Figure S3). Trace yielded about 17 
matching peptide masses, representing about 30-35% coverage for L-plastin. Peptide sequences identified 
in MS are highlighted in red (Figure S3). Similarly, trace yielded about 22 matching peptide masses, 
representing about 22-28% coverage for cortactin (data not shown). Peptides corresponding to proteins 
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such as, c-Src, gelsolin, vimentin, Arp 2, gCap39, actin, fyn, vacuolar H+ATPase B2, Cathepsin D were 
also identified in MS. A list is provided in the as Table S1.    
Real time RT-PCR analysis— Observations from several laboratories including our own demonstrated 
that several signaling molecules are involved in the reorganization of actin cytoskeleton during migration 
and bone resoprtion  To investigate further we quantitated the mRNAs using real-time PCR analysis 
(Figure S4). Thirteen genes were analyzed from the list of genes shown in Table S2. We determined the 
time course of bone particles effect on gene expression for four different time points (Figure S4). 
Although there was a decrease in L-plastin protein at 18-20h (Figures 3 and S1), a significant increase in 
mRNA (2-3 fold) was observed in real time RT-PCR analysis. The expression level of L-plastin did not 
change to a great extent at 4h, 8h, and 12h. There was a significant increase in the expression of Src and 
Rho GTPase was observed at all four time points tested. However, expression of cortactin, integrin beta 3 
and Rho kinase was increased at 4h and 18h but decreased to either control level (cortactin) or below 
control level (beta 3 and Rho kinase) at 8 and 12 h. Addition of bone for 4-18h had no effect on the 
expression levels of  WASP, Rho GAP, PYK2, Arp3, and alpha v. A time dependent increase in the 
expression of gelsolin was observed at 8, 12, and 18h.  
We have shown in real time RT-PCR analysis that there are no changes in expression of L-plastin mRNA 
level during incubation for 4, 8, and 12h and an increase was observed at 18h. We hypothesized that the 
expression levels of L-plastin protein may be gradually reduced from 4-18h and increased after 18h.  
Therefore, we analyzed the L-Plastin protein levels as shown below. Changes in the RNA levels 
correspond with the protein levels shown in Figure 3. It is possible that the cyclical changes in the 
RNA/protein levels correspond with the formation of actin aggregates.  Mass spectrometry and real time 
analyses revealed some of the key proteins involved in osteoclast bone resorption 
Analysis of the effects of mineralized and demineralized bone particles on osteoclast function— Next, we 
have determined the effects of demineralized bone particles on osteoclasts migration and adhesion and 
changes in the protein levels (Figure S5) Bone particles from the long bone of mice were treated with 
14% EDAT for two weeks and the demineralized bone particles (DMBP) were extensively with sterile 
PBS and pH was normalized to 7.2 prior to adding to osteoclasts. The texture of DMBPs was different 
from mineralized particles. DMBPs were inseparable and slimy in the culture medium. It is less dense 
(i.e. noticeably semi-transparent) and more fibrous under microscope (Figure S5). Upon incubation for 2-
3h at 370C, the demineralized bone particles were found surrounded and adhered by osteoclasts. 
Migration of osteoclasts towards the particles was observed (Figure S5). Lysates made from 
osteoclasts treated with demineralized and mineralized bone materials for 16-18h were subjected to 
SDS-PAGE. Similar decrease in the levels of L-plastin and increase in cortactin was observed in 
osteoclasts treated with bone particles (Figure S5B, lane 2). Although a decrease in L-plastin level was 
observed in osteoclasts treated with DMBPs, cortactin level was either remained the same or decreased 
(lane 3) below control levels in these osteoclasts (lane 1). This suggests that activation of cortactin by 
integrin occurs during bone resorption in the presence of mineralized matrix which may not be necessary 
for the activity of L-plastin.   
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FIGURE LEGENDS 
FIGURE S1. Analysis of changes in the organization of GFP-labeled actin in osteoclasts incubated 
with dentine slices in vivo. Osteoclasts expressing were added with dentine slices. Cells migrating 
towards and attached to dentine slices were visualized at 2-4h (A), 4-6h (B), and 10-12h (C). Migrating 
osteoclasts which express GFP-actin are indicated by arrow heads (A and C). The dentine is shown in red 
(pseudocolor) by the reflected light (A”-C”). Osteoclasts expressing actin protein is shown in green (A’-
C’). Overlay images (A-C) show osteoclasts expressing GFP-actin (green) and bone (red). Two resorption 
pits were found adjacent to each other (indicated as 1 and 2 in C”). Wavy arrow points to actin aggregate. 
Asterisks indicate organization of a membrane-like structure opposite to the adhesion zone to bone. DSR- 
Disassembled sealing ring; SR- Sealing ring.  
FIGURE S2. Two dimensional electrophoresis (2DGE) of lysates made from OCs treated with (+) 
and without (-) bone for 16-18h. Circles in Figure A indicate the proteins that are down regulated in 
OCs treated with bone (B). Upregulated proteins are indicated by arrows in osteoclasts treated with bone 
(+) (B). About 18 unique, 12 down regulated and 21 up regulated spots were identified by Z3 analysis. 
The protein spots that demonstrated a significant change (p<0.001) in abundance between the protein 
fractions of untreated and treated osteoclasts were selected for further characterization using mass 
spectrometry. Those proteins are indicated with numbers (1 and 2) in panels A and B (1’ and 2’). A 
significant increase in cortactin (1 and 1’) and decrease in L-plastin (2 and 2’) level was observed in 
osteoclasts treated with bone (+ bone in panel C). 
FIGURE S3.  Mass spectrometry and protein analysis. A. Tryptic peptides of L-plastin found in mass 
spectrometry are shown in red. B. A representative mass spectrum of one of the peptides 
(FSLVGIAGQDLNEGNR-highlighted in green in A) is provided in the graph. 
Table S1: Mass spectrometry results from osteoclasts subjected to bone resorption in the 
presence of bone particles are provided.  
FIGURE S4. Real-time quantitative PCR analysis. TABLE S2: Primer used for real time PCR are 
provided. Primers were designed using Primer Express software (Applied Biosystems Group). Graph: 
mRNA expression of indicated genes in osteoclasts treated with bone at the indicated time (see insert) is 
provided.  Untreated osteoclasts were used as controls. Results are reported as fold change in mRNA 
expression normalized to 18S ribosomal RNA and relative to control untreated RNA. Data shown are 
mean±SEM of three independent osteoclast preparations and experiments. ***p<0.001, 
**p<0.01,*p<0.05 vs. control osteoclasts untreated with bone.  
TABLE S2: Real time PCR analysis: Primers used for the indicated proteins are provided.   
FIGURE S5. Analysis of the expression profile of proteins and cell shape changes in 
osteoclasts treated with demineralized bone particles (DMBPs). Treatment of osteoclasts with 
bone particles were performed as described in the Methods section. DMBPs were added to 
mature osteoclast cultures (100μg/well in a six well cell culture plate). Pictures were taken in an 
inverted phase contrast microscope. Migration and adhesion of osteoclasts were observed at 2-3h 
(A). About ~300μg of lysate proteins made from osteoclasts incubated with normal (B, lane 2) 
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and DMBPs (lane 3) for 16-18h were subjected to 10% SDS-PAGE analysis. Cortactin (Cttn) 
and L-plastin (LPL) are indicated by arrows.  
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Q61233|PLSL_MOUSE Plastin-2 - Mus
musculus (Mouse)
MARGSVSDEEMMELREAFAKVDTDGNGYISCNELND
LFKAACLPLPGYRVREITENLMATGDLDQDGKISFDEF
IKVFHGLKSTEVAKTFRKAINKKEGICAIGGTSEQSSVG
TQHSYSEEEKYAFVNW INKALENDPDCRHVIPMNPNT
DDLFNAVGDGIVLCKMINLSVPDTIDERTINKKKLTPFTI
QENLNLALNSASAIGCHVVNIGAEDLKEGKPYLVLGLL
WQVIKIGLFADIELSRNEALIALLREGESLEDLMKLSPE
ELLLRWANYHLENAGCTKITNFSTDIKDSKAYYHLLEQ
VAPKGDEEGIPAVVIDMSGLREKDDIQRAECMLQQAE
RLGCRQFVTATDVVRGNPKLNLAFIANLFNKYPALHKP
ENQDIDWGALEGETREERTFRNWMNSLGVNPRVNHL
YSDLSDALVIFQLYEKIKVPVDWNRVNKPPYPKLGGN
MKKLENCNYAVDLGKNQAKFSLVGIAGQDLNEGNRT
LTLALVWQLMRRYTLNILEDIGGGQKVNDDIIVNWVNT
TLKEAQKSSSIASFKDPKISTSLPVLDLIDAIQPGSINYD
LLKTENLDDEEKLNNAKYAISMARKIGARVYALPEDLV
EVNPKMVMTVFACLMGKGMKRV
A
B
Figure S3 
Figure S2 
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Protein Name Accession number Protein probability 
Sorcerer 
percent 
coverage 
Number 
peptides 
(-) Bone 
Isoform C of Lamin-A\C,Isoform A of Lamin-A\C NP_001002011.1 1 2.4 3
Plastin-2 or L-plastin NP_032905.2 1 30 17
Transketolase NP_033414.1 1 2.9 1
Myosin-4 NP_034988.2 1 1.3 2
D-amino acid oxidase 1,D-amino-acid oxidase NP_034148.2 1 3.2 1
Zfp473 protein,MKIAA1141 protein (Fragment),Zinc finger 
protein 473 homolog NP_848849.2 0.98 1.2 31
diacylglycerol kinase, iota isoform 1 NP_001074675.1  0.9 1.3 3
Isoform 2 of Teneurin-3 NP_035986.2 0.78 0.8 2
Filamin-B NP_598841.1 0.74 0.6 3
Isoform 2 of E3 ubiquitin ligase TRIAD3 NP_542128.2 0.69 1.5 1
LYR motif-containing protein 1 NP_083886.1 0.67 7.4 3
mannose-6-phosphate receptor binding protein 1 NP_080112.1 0.67 23.8 3
Probable ATP-dependent RNA helicase DDX28  NP_082314.1 0.63 1.7 1
Nuclear RNA export factor 7 NP_570958.1 0.57 2.2 3
toll-interleukin 1 receptor (TIR) domain- containing adaptor 
protein(blast)  NP_473437.1 0.56 6.2 1
leukotriene A4 hydrolase NP_032543.2 0.56 4.6 1
Hira protein NP_034565.2 0.53 2.4 1
Rab proteins geranylgeranyltransferase component A 1 XP_996584.1 0.49 5.7 3
Myosin-11 NP_038635.1  0.49 1.1 2
Limb bud and heart XP_984828.1  0.49 15.2 1
CCR4-NOT transcription complex, subunit 10 NP_058573.2 0.48 1.5 1
sideroflexin 5 NP_848754.1 0.48 7.2 1
Isoform 3 of  ULK3 XP_930106.2 0.46 5.4 1
IFN-response-binding factor 1 P22560  0.44 3.5 1
zinc finger protein 507 XP_001002219.1 0.41 1.5 1
Ankyrin repeat and BTB\POZ domain-containing protein 2 NP_849221.2  0.4 1.2 1
Tcte-1 peptide NP_038716.2 0.4 2.2 1
WAS protein family, member 2 (blast) NP_700472.1 0.39 1.2 1
Polycystic kidney disease 1 protein NP_038658.2 0.38 0.3 1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21,Nucleolar RNA NP_080814.1 0.37 1.8 1
Table S1 
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helicase 2 
P47 protein (blast) XP_977730.1 0.36 3.7 1
heterogeneous nuclear ribonucleoprotein H3 NP_001073293.1 0.34 3.9 1
Fanconi anemia, complementation group E XP_996088.1 0.33 2.7 1
Isoform 3 of Phosphoinositide 3-kinase regulatory subunit 6 NP_001004435.1 0.32 3.9 1
Probable G-protein coupled receptor 55 NP_001028462.2 0.32 3 2
radial spokehead-like 2a (blast) NP_080065.3 0.32 6.4 1
Salivary glue protein Sgs-4 precursor  XP_920575.1 0.32 0.9 3
STYK1 NP_766479.1  0.32 2.9 3
ezrin-binding partner PACE-1 NP_083052.1 0.32 2 1
zinc finger protein 62  (blast) NP_001020017.1 0.3 1.6 1
 protein phosphatase 1A, magnesium dependent (blast) NP_067366.1  0.3 3.2 1
Angiotensin-converting enzyme, somatic isoform precursor XP_110936.5  0.29 0.9 2
synaptosomal-associated protein 23 (blast) NP_033248.1 0.28 5 1
ADAM 18 precursor XP_988097.1 0.28 1.3 2
BCL2-like 12 (proline rich) (blast) NP_083686.1  0.28 3.5 1
Isoform 1 of von Willebrand factor precursor NP_073725.2 0.27 0.4 4
VIP36-like protein precursor XP_892360.1 0.26 3.5 1
Hypothetical protein Golgin-160-like XP_139904.5 0.24 2.3 1
Zinc finger CCHC domain-containing protein 10 NP_080755.2 0.24 3.9 1
ubiquitin specific protease 31 XP_357781.3  0.24 1.3 1
Beta-1,4 N-acetylgalactosaminyltransferase 2 NP_032107.1  0.24 3.1 1
cortactin(blast) NP_031829.2  0.23 3 7
Mannose-6-phosphate receptor-binding protein 1 NP_080112.1  0.23 2.5 1
 serine (or cysteine) peptidase inhibitor, clade A, member 3H NP_001030042.2 0.23 2.2 1
Transcriptional intermediary factor 1 delta NP_862901.2 0.23 1.5 1
 Ras and Rab interactor 2 (blast) NP_083000.4 0.22 0.8 1
growth factor, erv1 NP_075527.2 0.22 6.1 1
Isoform GluR6-2 of Glutamate receptor NP_034478.1  0.22 1.5 1
BTB (POZ) domain containing 12 NP_803423.2 0.22 0.7 1
calcium and integrin binding 1 (calmyrin)(blast)  NP_036000.1 0.22 4.2 1
laminin,beta 2(blast) NP_032509.2 0.22 1.7 1
Isoform 3 of Kelch-like protein 26 NP_742049.1 0.21 2.7 1
gem (nuclear organelle) associated protein 4 (blast) NP_796341.1 0.21 1.2 1
ATP-dependent RNA helicase DDX41 NP_598820.1  0.21 3.7 1
 
9 
 
(+) Bone 
Matrix Metalloproteinase 9 NM_013599 0.68 13 9
Myosin-4 NP_034988.2 1 3 5.15
Myosin-1  NP_001074688.1  1 3 5.15
mannosidase 2  O54782  0.86 1 1.5
Nuclear RNA export factor 7 NP_570958.1 0.73 3 1.55
Zfp473 protein NP_848849.2 0.65 13 7.3
high density lipoprotein binding protein (blast) Q3U4Z7 0.62 1 1.09
Isoform 2 of Teneurin-3 NP_035986.2 0.54 3 1.87
Fat4 Q2PZL6 0.47 1 0.83
GDP-mannose 4,6 dehydratase Q8K0C9 0.42 2 1.24
Olfactory receptor 681 NP_997440.1 0.38 2 1.06
ATP-binding cassette transporter sub-family A member 9 
(blast) NP_671753.1 0.3 1 0.53
tubulin, beta 4(blast) NP_033477.2 0.24 1 0.41
p47 protein (blast) XP_977730.1 0.22 3 1.02
Isoform 1 of von Willebrand factor precursor NP_073725.2 0.21 5 0.85
mannose-6-phosphate receptor binding protein 1 NP_080112.1  0.2 3 0.49
6-phosphogluconate dehydrogenase(blast) NP_001074743.1 1 10.2 10
Phosphoglycerate kinase 1 NP_032854.2 1 18.3 5
Vimentin NP_035831.2 1 5.4 4
isocitrate dehydrogenase 1 (NADP+), soluble (blast) NP_034627.2 1 11.4 3
gelsolin [Mus musculus](blast) NP_666232.2 1 17.5 16
actin-related protein 2 [Mus musculus](blast) NP_082789.1  1 19.1 12
Isoform 1 of Rab GDP dissociation inhibitor beta NP_005334.1 0.98 2.7 1
Cathepsin D precursor NP_035616.1 0.97 7.8 1
Citrate synthase, mitochondrial precursor NP_080720.1  0.86 2.4 3
protein-tyrosine kinase fyn [Mus musculus]   (blast)  NP_032080.1  0.61 8 9
C-Src kinase NM_001025395 0.85 13 18
SMC5 protein NP_722503.1 0.2 1.2 1
Vacuolar ATP synthase catalytic subunit A XP_898621.1  1 10.8 23
71 kDa protein,Heat shock cognate 71 kDa protein P97805 0.83 2.7 1
Protein FAM3D precursor NP_001034283.1  0.68 2.4 10
Isoform 2 of Apoptosis-inducing factor-like NP_035986.2 0.45 0.8 1
Cathepsin K NP_031828 0.6 12.3 16
6-phosphogluconate dehydrogenase,  NP_001074743.1 1 16.8 12
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Vimentin NP_035831.2 1 13.3 7
vacuolar H+ATPase B2 [Mus musculus](blast) NP_031535.2 1 4.8 4
Isoform 1 of Rab GDP dissociation inhibitor beta NP_005334.1 1 7.6 2
Pyruvate kinase isozyme M2 P52480  1 6.6 2
actin-related protein 2 (blast) NP_082789.1  1 22.1 35
Creatine kinase B-type Q04447 1 32.5 81
enolase 1 NP_075608.1 1 16.2 10
Heterogeneous nuclear ribonucleoprotein H1 NP_067485.1 1 7.6 2
isocitrate dehydrogenase 1 (NADP+), soluble(blast) NP_034627.2 0.98 4.1 2
Elongation factor 1-gamma,49 kDa protein Q4FZK2 0.98 4 1
Citrate synthase, mitochondrial precursor NP_080720.1  0.93 2.4 6
Phosphoglycerate kinase 1 NP_032854.2 0.93 8.3 1
Nucleolin NP_035010.3 0.82 3 1
Sodium\potassium-transporting ATPase subunit beta-3 P97370  0.79 6.1 2
Isoform 2 of Teneurin-3 NP_035986.2 0.76 0.8 11
26S protease regulatory subunit S10B P62333 0.76 3.9 1
Isoform C of Lamin-A\C NP_001002011.1 0.72 1.7 1
Ubiquinol-cytochrome-c reductase complex core protein I Q9CZ13  0.65 4.4 1
Ubiquitin-protein ligase E3 component N-recognin-1 NP_033487.1  0.54 0.7 1
Cation-dependent mannose-6-phosphate receptor precursor P24668 0.52 6.5 1
Transient receptor potential cation channel subfamily M  NP_612174.1 0.5 0.7 1
S1 protein C2,Heterogeneous nuclear ribonucleoprotein A\B NP_001041526.1 0.49 4.9 1
Myosin IIIB2,myosin IIIB NP_796350.2 0.4 1 1
protein-tyrosine kinase fyn [Mus musculus](blast) NP_032080.1  0.35 1.9 1
vesicle-associated calmodulin-binding protein (blast) NP_663596.1 0.31 5.1 25
DVL-binding protein DAPLE NP_080957.2 0.29 0.7 2
Isoform 1 of Discs large homolog  NP_031888.2 0.27 1.7 1
ATPase, H+ transporting, V1 subunit A, isoform 1 NP_598587.2 1 3.2 8
Plastin-2 or L-Plastin NP_032905.2 1 12.3 13
Heat shock cognate 71 kDa protein XP_898621.1  1 9.6 7
Myosin-4 NP_034988.2 1 2.3 9
cortactin NP_031829.2  1 19.2 31
Isoform 2 of Teneurin-3 NP_035986.2 0.24 0.8 2
Stress-70 protein, mitochondrial precursor XP_998290.1 0.67 2.8 1
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Gene name Forward Reverse 
Arp3 
Gelsolin 
Integrin αv 
Integrin β3 
PTP-PEST 
Pyk2 
Rho 
Rho GAP 
Rho kinase 
WASP 
Actin 
18S  
GAPDH  
c-Src 
Plastin-2  
Cortactin 
5'- ctttgaaacccatcatcac  -3'     
5’- cttctgctaagcggtacatc  -3'     
5'- cctgaggtgcttcttaagtg  -3'  
5'- tcctctatgtggtggaag  -3'       
5'- agcattgcaggttatcagag  -3'   
5'- tgatacagaggggacagag  -3'  
5'- gcctctgtatctgcaaagag  -3'  
5'- agcagcatgactgttgtg  -3'   
5'- cagcttcttcacctgtcttc  -3'   
5'- ctgccatctagattctgctc  -3'   
5'- tcttccgccttaatacttc  -3'    
5'- acgaggaattcccagtaag  -3'  
5'- gaggaccaggttgtctcctg -3' 
5'- cttctctctgcctcagtgtc  -3'  
5'- taccgccatagcatcttc -3'  
5'- ggcttccttgagcaactgtc-3'   
5'- ttccattgatcttcccaatac -3' 
5'- agatggacaaccctcaaag -3'  
5'- ggcgaagtaaatgtaacctg -3' 
5'- tctttatacagcgggttg -3' 
5'- tccaaggcacttactgaatc -3'  
5'- catccaggtcaaactcac -3' 
5'- catcccattcttttgctaag -3' 
5'- gctgcttcaactctattg -3'  
5'- tttcagacagaaaggcactc -3'  
5'- gggaaagaaacccaaactac -3' 
5'- tagtcaagttcgaccgtc -3'  
5'- gagaccaaagccttcatac -3' 
5'- atgtaggccatgaggtccac -3' 
5'- tctgggatagagtagggatg -3'  
5'- ggaggcagatggacaaac -3' 
5'- gcaaggattctgcaggaaag -3' 
Figure S4 
Table S2 
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Figure S5 
